In the modern economy, human capital is the main strategic resource for development, which has a direct impact on economic growth and social welfare. The purpose of the research is to examine the features of human capital development in the context of current structural changes in the economy due to changes in technological and world economic paradigms, and to identify its parameters to be evaluated and managed. The subject of the research is economic relations arising in the process of formation and use of human capital at different stages of economic development. The main results of the research are as follows: determination of the main structural components of human capital (physiological, labor, social and intellectual), identification of the trends in their participation in value creation when changing technological and world economic paradigms, as well as identification of institutional elements that affect their development and use. The scope of the results obtained is determined by the possibility of including key parameters of human capital in strategic plans for socio-economic development and improving the competitiveness of the national economy.

The paper considers the state of the regenerative medicine market. The purpose of the work is to review the existing sources on the economic issues of regenerative medicine products and their introduction to the market. Due to the fact that the market for regenerative medicine is in growth stage, the number of sources is extremely limited. The review collected, analyzed and systematized data on the volume and dynamics of the market, its financing, drivers and barriers, provides a list of regulatory documents regulating the market, government support measures and opportunities for start-up entrepreneurs. The performed research characterizes the market of regenerative medicine products as a market with strong potential for growth in the next decade. The results obtained helped to identify problematic aspects of the market that require examine issues by specialized specialists. Subject to consideration of negative reviews of the federal law No. 180-FZ “On biomedical cell products” adopted on June 23, 2016, continued active state support and legal regulation, products and services of the regenerative medicine market will be able to win their niche and compete with current drugs and methods of treatment.

No abstract